Sefer Gezer to Myelodysplastic Syndromes
This is a "connection" page, showing publications Sefer Gezer has written about Myelodysplastic Syndromes.
Connection Strength
0.250
-
Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma. 2004 Oct; 45(10):2099-104.
Score: 0.054
-
Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res. 2004 Aug; 28(8):791-803.
Score: 0.053
-
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001 Aug 15; 98(4):958-65.
Score: 0.043
-
Biologic characteristics of patients with hypocellular myelodysplastic syndromes. Leuk Res. 1999 Apr; 23(4):357-64.
Score: 0.037
-
Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine. Exp Hematol. 1997 Jun; 25(6):530-5.
Score: 0.032
-
Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood. 1996 Oct 01; 88(7):2640-7.
Score: 0.031